Therma Bright Inc.

  • ISIN: CA4760231064
  • Land: .

Nachricht vom 12.10.2017 | 19:12

The Jenex Corporation Reports Promising Initial Results on Zika Virus Testing with TherOZap(TM)

DGAP-News: The Jenex Corporation / Key word(s): Miscellaneous

12.10.2017 / 19:12
The issuer is solely responsible for the content of this announcement.


Toronto, Ontario--(Newsfile Corp. - October 12, 2017) - The Jenex Corporation (TSXV: JEN.H) ('Jenex' or the 'Company'), a progressive medical device technology company, today announces that it has received promising initial results on the Zika virus testing with TherOZap.

Dr. Alyson Kelvin at UHN reported the following:

'To evaluate the effectiveness of the Jenex TherOZap device against the infectivity of Zika virus, cells were infected with a range of Zika virus doses and treated with the Jenex device with heat. In the cells that received the lowest viral dose, initial results showed infected cells that had been treated with the Jenex TherOZap device had a markedly lower cytopathic effect compared to infected cells that did not receive treatment. These preliminary results need to be confirmed through repeated testing as well as by measurement of virus viability. Cytopathic effect is a measure of cellular pathogenesis and cellular viability in relation to viral infection; results of a viral replication assay and measurements of live viral activity are pending.'

Mr. Rob Fia, CEO, commented:

'We are pleased with the initial test results on the Zika Virus with our patent pending TherOZap™ technology. Jenex is excited about these initial tests results and we look forward to further data as it becomes available from Techna Institute at UHN. Jenex will have more to report to over the next several weeks.'

About Jenex:

Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs.  Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.

Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997.

The Jenex Corporation trades on the NEX (TSXV: JEN.H). For more information visit: www.thejenexcorporation.com or www.therozap.com.

About Techna Institute:

Techna is an institute of the University Health Network, in collaboration with the University of Toronto, focused on the accelerated development and exploitation of technology for improved health. Techna is designed to shorten the time interval from technology discovery and development to application for the benefit of patients and the health care system. It also stimulates and facilitates the innovation cycle through a continuum of clinically driven innovation, technology & process development, and translational research. For more information visit: technainstitute.com.

FORWARD LOOKING STATEMENTS

Certain statements in this news release constitute 'forward-looking' statements. These statements relate to future events or the Company's future performance and include laboratory tests involving TherOZap™, as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company may not complete the commercialization or marketing of its products as described in this news or attract capital in the future. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information please contact:
The Jenex Corporation
Rob Fia
CEO & Chairman
rfia@thejenexcorporation.com

NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES

Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/29660


12.10.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Interview im Fokus

PANTAFLIX: „Starkes Momentum“

Die PANTAFLIX AG ist kraftvoll in allen Geschäftsbereichen unterwegs und will neue Geschäftsfelder erschließen. „Unsere VoD-Plattform wächst rasant. Für PANTAFLIX eröffnen sich derzeit global gesehen Möglichkeiten, die es bis vor Kurzem noch gar nicht gab.“ Vorstandsvorsitzender (CEO) Stefan Langefeld und Chief Production Officer (CPO) Nicolas Paalzow erklären im Financial.de-Interview die nächsten Schritte des Medienkonzerns.

GBC im Fokus

Homes & Holiday AG – Spezialist für Ferienimmobilien jetzt an der Börse

Seit 6.7. ist die Aktie der Home & Holiday AG nun an der Börse München im Qualitätssegment m:access gelistet. Der Handel auf Xetra und Frankfurt ist ebenfalls erfolgt. Damit ist der erste deutsche Ferien-Immobilien-Spezialist auf dem Parkett. Inklusive Pre-IPO-Kapitalerhöhung sind Homes & Holiday rund 5,8 Mio. Euro zur Wachstumsbeschleunigung zugeflossen. Der TOP-3 Makler aus Mallorca will nun noch stärker expandieren. Unser Research ist von den Zukunftsperspektiven überzeugt und empfiehlt die Aktie mit einem Kursziel von 4,83 Euro zum Kauf.

Aktuelle Research-Studie

curasan AG

Original-Research: curasan AG (von Montega AG): Halten

20. Juli 2018